SEB Asset Management AB Buys Shares of 200,108 BioNTech SE Sponsored ADR $BNTX

SEB Asset Management AB bought a new stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 200,108 shares of the company’s stock, valued at approximately $17,804,000.

Several other institutional investors also recently modified their holdings of the business. GSK plc acquired a new position in BioNTech in the fourth quarter valued at approximately $84,711,000. BNP Paribas Financial Markets grew its holdings in BioNTech by 43.0% during the 4th quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company’s stock worth $150,235,000 after acquiring an additional 474,796 shares during the period. Bank of America Corp DE grew its holdings in BioNTech by 344.4% during the 3rd quarter. Bank of America Corp DE now owns 573,356 shares of the company’s stock worth $56,544,000 after acquiring an additional 444,332 shares during the period. Voloridge Investment Management LLC bought a new stake in shares of BioNTech during the 4th quarter valued at $41,656,000. Finally, Davern Capital Partners LP bought a new stake in shares of BioNTech during the 4th quarter valued at $35,340,000. Institutional investors and hedge funds own 15.52% of the company’s stock.

Insider Transactions at BioNTech

In other BioNTech news, COO Sierk Poetting sold 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $110.56, for a total transaction of $5,528,000.00. Following the sale, the chief operating officer directly owned 399,387 shares in the company, valued at approximately $44,156,226.72. This trade represents a 11.13% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 19.20% of the company’s stock.

BioNTech Stock Up 0.7%

Shares of BioNTech stock opened at $92.16 on Tuesday. BioNTech SE Sponsored ADR has a 1 year low of $79.52 and a 1 year high of $124.00. The business has a 50-day moving average of $91.32 and a two-hundred day moving average of $97.81. The company has a market capitalization of $23.31 billion, a P/E ratio of -15.67 and a beta of 1.32. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.80 and a quick ratio of 8.74.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Monday, May 4th. The company reported ($2.26) EPS for the quarter, topping analysts’ consensus estimates of ($2.52) by $0.26. BioNTech had a negative return on equity of 5.30% and a negative net margin of 44.39%.The company had revenue of $136.71 million for the quarter, compared to analyst estimates of $207.42 million. During the same quarter last year, the firm posted ($1.73) earnings per share. BioNTech’s revenue was down 35.4% compared to the same quarter last year. As a group, equities analysts predict that BioNTech SE Sponsored ADR will post -5.79 EPS for the current year.

BioNTech announced that its Board of Directors has initiated a stock buyback program on Thursday, May 7th that authorizes the company to buyback $1.00 billion in shares. This buyback authorization authorizes the company to buy up to 4.2% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s leadership believes its shares are undervalued.

Wall Street Analysts Forecast Growth

BNTX has been the topic of several recent research reports. Berenberg Bank reduced their price target on BioNTech from $155.00 to $140.00 and set a “buy” rating on the stock in a research report on Tuesday, May 12th. UBS Group upgraded BioNTech from a “neutral” rating to a “buy” rating and upped their price objective for the company from $117.00 to $135.00 in a report on Wednesday, May 27th. Jefferies Financial Group reissued a “buy” rating on shares of BioNTech in a research note on Monday, June 1st. Wall Street Zen upgraded BioNTech from a “sell” rating to a “hold” rating in a report on Saturday. Finally, Sanford C. Bernstein restated a “market perform” rating on shares of BioNTech in a research report on Friday, June 5th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, BioNTech presently has a consensus rating of “Moderate Buy” and a consensus price target of $129.12.

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.